{"id":"placebo-dpi","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo product, it contains no active pharmaceutical ingredient and serves as a control comparator in clinical trials or as a reference standard. It is administered through a dry powder inhaler (DPI) device to match the delivery route and patient experience of active respiratory medications without conferring therapeutic benefit.","oneSentence":"Placebo DPI is an inert formulation delivered via dry powder inhaler that produces no pharmacological effect.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:48.617Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control / comparator product"}]},"trialDetails":[{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT07380152","phase":"PHASE1","title":"Corticosteroid Therapy in Pulmonary Sequelae of Covid-19","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2021-08-10","conditions":"COVID-19 Pulmonary Complications","enrollment":100},{"nctId":"NCT04636814","phase":"PHASE3","title":"A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-07-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3973},{"nctId":"NCT07344558","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Mannkind Corporation","startDate":"2025-12-22","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":24},{"nctId":"NCT06029595","phase":"PHASE2","title":"Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-26","conditions":"Uncontrolled Asthma","enrollment":517},{"nctId":"NCT04636801","phase":"PHASE3","title":"A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-07-14","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":4710},{"nctId":"NCT06519968","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-07-15","conditions":"Healthy Participants","enrollment":56},{"nctId":"NCT06795906","phase":"PHASE1","title":"A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-01-28","conditions":"Asthma","enrollment":24},{"nctId":"NCT04643158","phase":"PHASE2","title":"Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT07133880","phase":"PHASE4","title":"Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators","status":"RECRUITING","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2023-12-05","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":72},{"nctId":"NCT03822455","phase":"PHASE2","title":"A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis","status":"TERMINATED","sponsor":"AlgiPharma AS","startDate":"2019-05-16","conditions":"Cystic Fibrosis","enrollment":15},{"nctId":"NCT03766399","phase":"PHASE1","title":"A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-11-30","conditions":"Asthma","enrollment":131},{"nctId":"NCT01502371","phase":"PHASE2","title":"A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-01-25","conditions":"Asthma","enrollment":583},{"nctId":"NCT00521599","phase":"PHASE4","title":"A Study of the Equivalent Effectiveness of 400 mcg Mometasone Furoate Using Two Different Dry Powder Inhalers in Moderate Asthmatics (Study P04828)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2007-05","conditions":"Asthma","enrollment":672},{"nctId":"NCT01258803","phase":"PHASE2","title":"A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-12","conditions":"Asthma","enrollment":92},{"nctId":"NCT00394355","phase":"PHASE4","title":"Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Asthma","enrollment":566},{"nctId":"NCT00635882","phase":"PHASE2","title":"Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-02","conditions":"Asthma, Airway Inflammation","enrollment":93},{"nctId":"NCT00127166","phase":"PHASE3","title":"Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-12","conditions":"Exercise Induced Asthma","enrollment":154},{"nctId":"NCT01803555","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07-04","conditions":"Asthma","enrollment":605},{"nctId":"NCT02257177","phase":"PHASE1, PHASE2","title":"RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients","status":"COMPLETED","sponsor":"Galecto Biotech AB","startDate":"2014-09","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":60},{"nctId":"NCT03758950","phase":"PHASE2","title":"Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2","status":"COMPLETED","sponsor":"Jeffrey Glassberg","startDate":"2018-11-29","conditions":"Sickle Cell Disease","enrollment":80},{"nctId":"NCT04813354","phase":"PHASE4","title":"A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-04-14","conditions":"Asthma","enrollment":114},{"nctId":"NCT05628740","phase":"PHASE1","title":"Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175","status":"COMPLETED","sponsor":"Nocion Therapeutics","startDate":"2022-02-07","conditions":"Refractory Chronic Cough","enrollment":24},{"nctId":"NCT04769869","phase":"PHASE1","title":"A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-08","conditions":"Asthma","enrollment":110},{"nctId":"NCT03698448","phase":"PHASE2, PHASE3","title":"A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis","status":"WITHDRAWN","sponsor":"AlgiPharma AS","startDate":"2021-09-01","conditions":"Cystic Fibrosis","enrollment":""},{"nctId":"NCT04759807","phase":"PHASE1","title":"A Phase 1b Study of PUR1800 in Patients With COPD","status":"COMPLETED","sponsor":"Pulmatrix Inc.","startDate":"2021-01-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":18},{"nctId":"NCT04233814","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Rein Therapeutics","startDate":"2020-01-20","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":71},{"nctId":"NCT01056159","phase":"PHASE1","title":"A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-01","conditions":"Asthma","enrollment":47},{"nctId":"NCT02227394","phase":"PHASE2","title":"Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-08","conditions":"Asthma, Asthma Chronic, Asthma Bronchial","enrollment":20},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT02000609","phase":"PHASE2","title":"A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of \"Nexthaler\" Dry Powder Inhaler in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2013-12","conditions":"COPD","enrollment":49},{"nctId":"NCT02018549","phase":"PHASE2","title":"An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPI","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2013-12","conditions":"COPD","enrollment":72},{"nctId":"NCT02579850","phase":"PHASE3","title":"2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1532},{"nctId":"NCT01738087","phase":"PHASE2","title":"Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-11","conditions":"Asthmatic","enrollment":30},{"nctId":"NCT03960606","phase":"PHASE2","title":"Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis","status":"TERMINATED","sponsor":"Pulmatrix Inc.","startDate":"2019-07-31","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":7},{"nctId":"NCT04480879","phase":"PHASE1","title":"Evaluation of AZD8154 Concentrations in Blood","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-07-17","conditions":"Asthma","enrollment":10},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03590379","phase":"PHASE2","title":"Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-06-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":366},{"nctId":"NCT03478657","phase":"PHASE4","title":"An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-18","conditions":"Asthma","enrollment":222},{"nctId":"NCT03965871","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2019-03-28","conditions":"Bipolar Depression","enrollment":88},{"nctId":"NCT03645434","phase":"PHASE2","title":"A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-10-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":73},{"nctId":"NCT03622112","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-01-02","conditions":"Asthma","enrollment":808},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":"Asthma","enrollment":425},{"nctId":"NCT00742248","phase":"PHASE2","title":"Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2004-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT03004417","phase":"PHASE2","title":"Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-10-31","conditions":"COPD","enrollment":61},{"nctId":"NCT02680197","phase":"PHASE2","title":"Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-02-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":262},{"nctId":"NCT01703052","phase":"PHASE1","title":"Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":74},{"nctId":"NCT02573870","phase":"PHASE2","title":"Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":63},{"nctId":"NCT03227445","phase":"PHASE4","title":"Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT03965858","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2019-02-25","conditions":"Major Depressive Disorder","enrollment":88},{"nctId":"NCT03034915","phase":"PHASE4","title":"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2696},{"nctId":"NCT04219982","phase":"PHASE2, PHASE3","title":"DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness","status":"TERMINATED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2018-06-29","conditions":"Motion Sickness","enrollment":23},{"nctId":"NCT02982187","phase":"PHASE4","title":"A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":160},{"nctId":"NCT02570165","phase":"PHASE2","title":"Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":325},{"nctId":"NCT02729051","phase":"PHASE3","title":"Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1055},{"nctId":"NCT02794480","phase":"PHASE4","title":"Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-22","conditions":"Asthma","enrollment":324},{"nctId":"NCT02059434","phase":"PHASE1","title":"Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Asthma","enrollment":55},{"nctId":"NCT02971293","phase":"PHASE2","title":"Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-12-15","conditions":"Chronic Obstructive Pulmonary Disease COPD","enrollment":42},{"nctId":"NCT03920644","phase":"PHASE3","title":"Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels","status":"UNKNOWN","sponsor":"Naval Aeromedical Research Unit, Dayton","startDate":"2019-04","conditions":"Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness","enrollment":320},{"nctId":"NCT02291016","phase":"NA","title":"COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers","status":"COMPLETED","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2015-02","conditions":"COPD Exacerbation","enrollment":7},{"nctId":"NCT03028142","phase":"PHASE2","title":"The Effects of RPL554 in Addition to Tiotropium in COPD Patients","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2017-01","conditions":"Chronic Obstructive Pulmonary Disease Moderate","enrollment":30},{"nctId":"NCT02814656","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT02986321","phase":"PHASE2","title":"A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1130},{"nctId":"NCT02777827","phase":"PHASE1","title":"A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-21","conditions":"Asthma","enrollment":30},{"nctId":"NCT02661438","phase":"NA","title":"Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-01-12","conditions":"Bronchiectasis, Pulmonary Disease, Chronic Obstructive","enrollment":46},{"nctId":"NCT01966107","phase":"PHASE4","title":"Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-10-16","conditions":"COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD","enrollment":3635},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT03707678","phase":"PHASE2","title":"A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-21","conditions":"Asthma","enrollment":""},{"nctId":"NCT02786927","phase":"PHASE4","title":"Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-21","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":214},{"nctId":"NCT02275052","phase":"PHASE4","title":"A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":198},{"nctId":"NCT02567708","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT03407872","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2017-12-09","conditions":"Healthy Volunteers","enrollment":63},{"nctId":"NCT01793883","phase":"PHASE2","title":"Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza","status":"COMPLETED","sponsor":"Biota Scientific Management Pty Ltd","startDate":"2013-05","conditions":"Influenza","enrollment":639},{"nctId":"NCT00995826","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Study of Multiple Doses of CS-8958","status":"COMPLETED","sponsor":"Biota Scientific Management Pty Ltd","startDate":"2009-04","conditions":"Influenza","enrollment":16},{"nctId":"NCT02022761","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma","status":"COMPLETED","sponsor":"Biota Scientific Management Pty Ltd","startDate":"2013-10","conditions":"Asthma","enrollment":32},{"nctId":"NCT01426009","phase":"PHASE2","title":"Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study","status":"COMPLETED","sponsor":"Sunovion Respiratory Development Inc.","startDate":"2011-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT01576718","phase":"PHASE2","title":"A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2012-04","conditions":"Asthma","enrollment":889},{"nctId":"NCT02453789","phase":"PHASE2","title":"A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection","status":"COMPLETED","sponsor":"AlgiPharma AS","startDate":"2015-02","conditions":"Cystic Fibrosis, Burkholderia Infection","enrollment":15},{"nctId":"NCT01651650","phase":"PHASE2","title":"An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-06","conditions":"Asthma","enrollment":41},{"nctId":"NCT01252758","phase":"PHASE2","title":"Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma","status":"WITHDRAWN","sponsor":"Acerus Pharmaceuticals Corporation","startDate":"2012-11","conditions":"Asthma","enrollment":""},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT02645253","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-01-12","conditions":"Asthma, Chronic Obstructive Pulmonary Disease COPD","enrollment":27},{"nctId":"NCT02796651","phase":"PHASE2","title":"Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-30","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":132},{"nctId":"NCT01764841","phase":"PHASE3","title":"Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-05-02","conditions":"Bronchiectasis","enrollment":416},{"nctId":"NCT03273127","phase":"PHASE1","title":"To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-21","conditions":"Asthma","enrollment":12},{"nctId":"NCT01210170","phase":"NA","title":"Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2010-10","conditions":"Asthma","enrollment":22},{"nctId":"NCT02152605","phase":"PHASE3","title":"A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":498},{"nctId":"NCT01957163","phase":"PHASE3","title":"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":619},{"nctId":"NCT03159442","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-06-19","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":25},{"nctId":"NCT01566773","phase":"PHASE2","title":"PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT02586506","phase":"PHASE4","title":"Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-01","conditions":"Asthma","enrollment":259},{"nctId":"NCT02576626","phase":"PHASE4","title":"Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD","status":"COMPLETED","sponsor":"Wouter H. van Geffen","startDate":"2015-12","conditions":"COPD","enrollment":40},{"nctId":"NCT02106832","phase":"PHASE3","title":"Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-04-30","conditions":"Bronchiectasis","enrollment":521},{"nctId":"NCT00279019","phase":"PHASE1","title":"Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":31},{"nctId":"NCT00515502","phase":"PHASE2","title":"Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-21","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":24},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT01189396","phase":"PHASE2","title":"Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006","status":"COMPLETED","sponsor":"Amphastar Pharmaceuticals, Inc.","startDate":"2010-07","conditions":"Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":27},{"nctId":"NCT01521377","phase":"PHASE1","title":"QTc Study GSK573719+GW642444","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":100},{"nctId":"NCT01165125","phase":"PHASE1","title":"A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Asthma","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo DPI","genericName":"Placebo DPI","companyName":"Amphastar Pharmaceuticals, Inc.","companyId":"amphastar-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo DPI is an inert formulation delivered via dry powder inhaler that produces no pharmacological effect. Used for Clinical trial control / comparator product.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":10,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}